By Josh White
Date: Tuesday 19 Aug 2025
(Sharecast News) - Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for schizophrenia.
By Iain Gilbert
Date: Thursday 10 Apr 2025
(Sharecast News) - Software group Cambridge Cognition said on Thursday that it has secured a £1.0m contract to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial.
By Josh White
Date: Wednesday 08 Jan 2025
(Sharecast News) - Cambridge Cognition announced the use of its 'CANTAB' cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for 'Cobenfy', a newly FDA-approved treatment for schizophrenia.
Currency | UK Pounds |
Share Price | 26.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 46.50 |
52 Week Low | 25.00 |
Volume | 13,805 |
Shares Issued | 41.94m |
Market Cap | £10.90m |
RiskGrade | 282 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
09:42 | 10,000 @ 27.00p |
08:32 | 3,805 @ 26.28p |
You are here: research